Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Guardant Health

Guardant Health Stock Sees RS Rating Jump To 83

A Relative Strength Rating upgrade for Guardant Health shows improving technical performance.

Investors Business Daily

Deciphering Disruption: Inside Cathie Wood's Latest Plays

Cathie Wood's recent stock market activity offers a glimpse into her evolving investment strategy and the potential of disruptive technologies.

MarketBeat

Stocks Showing Improving Market Leadership: Guardant Health Earns 82 RS Rating

A Relative Strength Rating upgrade for Guardant Health shows improving technical performance.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Guardant Health Pops 13% On An 'Impressive' Beat Following Exact Sciences' Flop

Guardant Health stock jumped Thursday on an "impressive" third-quarter report following the launch of its cancer detection test, Shield.

Investors Business Daily

Why Exact Sciences, Up 27%, Is 'Coiled To Snap Back' After Quarterly Beat

Exact Sciences stock bounded higher Thursday after beating second-quarter expectations, signaling a return to growth for Cologuard.

Investors Business Daily

Guardant Health Jumps — As Exact Sciences Slumps — On A Key FDA Move For Blood Tests

Guardant Health stock jumped Friday after an FDA panel recommended the agency approval Guardant's blood-based colon cancer screening test.

Investors Business Daily

Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales

Exact Sciences stock surged Tuesday after the company's colon cancer-screening rival, Freenome, unveiled the results of a pivotal study.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

A simple blood test can detect colorectal cancer early, study finds

At a time when colorectal cancer is rising, researchers say a blood test can detect 83% of people with the disease. If the FDA approves it the test would be another screening tool for early detection.

WEKU

New Blood Test Shows Promise For Colon Cancer Screening

Learn about promising advancements in colon cancer screening methods, including new blood tests and improved stool tests, offering hope for increased early...

Top News

A Hidden AI Stock to Add to Your Portfolio

Many AI techniques are already being used in healthcare, where the highest degree of accuracy is required. One such area is oncology testing and the cancer research programs of Guardant Health.

Barchart

Guardant Health Stock Sees Renewed Technical Strength

Guardant Health sees its Relative Strength Rating enter the 80-plus level.

Investors Business Daily

Guardant Health Stock Reaches 80-Plus Relative Strength Rating Benchmark

Guardant Health shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.

Investors Business Daily

Exact Sciences Rockets As Guardant's Blood Test Pales Vs. Cologuard

Guardant unveiled results for its colon cancer-detecting blood test that lagged rival Exact. GH stock crashed as EXAS stock jumped Friday.

Investors Business Daily

Europe Strikes Down Another Illumina Acquisition

A complicated merger situation for Illumina just got messier.

The Street

Get all your
news in one place.

100’s of premium titles.
One news app.

The Street

This Unpopular Move Could Save Invitae

Offloading a recent acquisition could accelerate the path to profitability – or an acquisition.

The Street

5 Headwinds Facing Liquid Biopsies in Colon Cancer Screening

Exact Sciences, maker of Cologuard, won't be dethroned anytime soon.

Benzinga

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD). The study met two co-primary objectives, associated with immunogenicity responses. Pfizer shares traded in a range of $48.55 to…

Benzinga

10 Biggest Price Target Changes For Monday

Morgan Stanley cut Guardant Health, Inc. (NASDAQ: GH) price target from $120 to $85. Guardant Health shares rose 4.3% to $40.99 in pre-market trading.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

What 6 Analyst Ratings Have To Say About Guardant Health

Over the past 3 months, 6 analysts have published their opinion on Guardant Health (NASDAQ:GH) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Guardant Health's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q4, Guardant Health's (NASDAQ:GH) reported sales totaled $108.11 million. Despite a 32.75% increase in earnings, the company posted a loss of $72.31 million.

Benzinga

10 Biggest Price Target Changes For Thursday

SVB Leerink lowered Guardant Health, Inc. (NASDAQ: GH) price target from $170 to $140. Guardant Health shares dropped 5.7% to $56.22 in pre-market trading.

Benzinga

Recap: Guardant Health Q4 Earnings

Guardant Health (NASDAQ:GH) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:03 PM. Here's what investors need to know about the announcement.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.